B Reix1, J-C Bernhard2, J-J Patard3, P Bigot4, A Villers5, E Suer6, N S Vuong2, G Verhoest7, Q Alimi7, J-B Beauval8, T Benoit8, F-X Nouhaud9, C Lenormand9, N Hamidi6, J Cai10, M Eto11, S Larre12, A El Bakhri12, G Ploussard13, A Hung10, N Koutlidis14, A Schneider14, J Carrouget4, S Droupy15, S Marchal15, A Doerfler16, S Seddik16, T Matsugasumi10, X Orsoni17, A Descazeaud17, C Pfister9, K Bensalah7, M Soulie8, I Gill10, V Flamand5. 1. Department of urology, university hospital of Lille, Lille, France. Electronic address: boris.Reix@gmail.com. 2. Department of urology, university hospital of Bordeaux, Bordeaux, France. 3. Department of urology, university hospital of Kremlin Bicêtre, Kremlin Bicêtre, France. 4. Department of urology, university hospital of Angers, Angers, France. 5. Department of urology, university hospital of Lille, Lille, France. 6. Department of urology, university hospital of Ankara, Ankara, Turkey. 7. Department of urology, university hospital of Rennes, Rennes, France. 8. Department of urology, university hospital of Toulouse, Toulouse, France. 9. Department of urology, university hospital of Rouen, Rouen, France. 10. USC institute of urology, university of Southern California, Los Angeles, United States. 11. Department of urology, university hospital of Kumamoto, Kumamoto, Japan. 12. Department of urology, university hospital of Reims, Reims, France. 13. Department of urology, university hospital of Saint-Louis, Paris, France. 14. Department of urology, university hospital of Dijon, Dijon, France. 15. Department of urology, university hospital of Nimes, Nimes, France. 16. Department of urology, university hospital of Caen, Caen, France. 17. Department of urology, university hospital of Limoges, Limoges, France.
Abstract
BACKGROUND: Partial nephrectomy (PN) is recommended as first-line treatment for cT1 stage kidney tumors because of a better renal function and probably a better overall survival than radical nephrectomy (RN). For larger tumors, PN has a controversial position due to lack of evidence showing good cancer control. The aim of this study was to compare the results of PN and RN in cT2a stage on overall survival and oncological results. METHOD: A retrospective international multicenter study was conducted in the frame of the French kidney cancer research network (UroCCR). We considered all patients aged≥18 years who underwent surgical treatment for localized renal cell carcinoma (RCC) stage cT2a (7.1-10cm) between 2000 and 2014. Cox and Fine-Gray models were performed to analyze overall survival (OS), cancer specific survival (CSS) and cancer-free survival (CFS). Comparison between PN and RN was realized after an adjustment by propensity score considering predefined confounding factors: age, sex, tumor size, pT stage of the TNM classification, histological type, ISUP grade, ASA score. RESULTS: A total of 267 patients were included. OS at 3 and 5 years was 93.6% and 78.7% after PN and 88.0% and 76.2% after RN, respectively. CSS at 3 and 5 years was 95.4% and 80.2% after PN and 91.0% and 85.0% after RN. No significant difference between groups was found after propensity score adjustment for OS (HR 0.87, 95% CI: 0.37-2.05, P=0.75), CSS (HR 0.52, 95% CI: 0.18-1.54, P=0.24) and CFS (HR 1.02, 95% CI: 0.50-2.09, P=0.96). CONCLUSION: PN seems equivalent to RN for OS, CSS and CFS in cT2a stage kidney tumors. The risk of recurrence is probably more related to prognostic factors than the surgical technique. The decision to perform a PN should depend on technical feasibility rather than tumor size, both to imperative and elective situation. LEVEL OF EVIDENCE: 4.
BACKGROUND: Partial nephrectomy (PN) is recommended as first-line treatment for cT1 stage kidney tumors because of a better renal function and probably a better overall survival than radical nephrectomy (RN). For larger tumors, PN has a controversial position due to lack of evidence showing good cancer control. The aim of this study was to compare the results of PN and RN in cT2a stage on overall survival and oncological results. METHOD: A retrospective international multicenter study was conducted in the frame of the French kidney cancer research network (UroCCR). We considered all patients aged≥18 years who underwent surgical treatment for localized renal cell carcinoma (RCC) stage cT2a (7.1-10cm) between 2000 and 2014. Cox and Fine-Gray models were performed to analyze overall survival (OS), cancer specific survival (CSS) and cancer-free survival (CFS). Comparison between PN and RN was realized after an adjustment by propensity score considering predefined confounding factors: age, sex, tumor size, pT stage of the TNM classification, histological type, ISUP grade, ASA score. RESULTS: A total of 267 patients were included. OS at 3 and 5 years was 93.6% and 78.7% after PN and 88.0% and 76.2% after RN, respectively. CSS at 3 and 5 years was 95.4% and 80.2% after PN and 91.0% and 85.0% after RN. No significant difference between groups was found after propensity score adjustment for OS (HR 0.87, 95% CI: 0.37-2.05, P=0.75), CSS (HR 0.52, 95% CI: 0.18-1.54, P=0.24) and CFS (HR 1.02, 95% CI: 0.50-2.09, P=0.96). CONCLUSION: PN seems equivalent to RN for OS, CSS and CFS in cT2a stage kidney tumors. The risk of recurrence is probably more related to prognostic factors than the surgical technique. The decision to perform a PN should depend on technical feasibility rather than tumor size, both to imperative and elective situation. LEVEL OF EVIDENCE: 4.
Authors: Christopher J Weight; Gregory Lieser; Benjamin T Larson; Tianming Gao; Brian R Lane; Steven C Campbell; Inderbir S Gill; Andrew C Novick; Amr F Fergany Journal: Eur Urol Date: 2010-05-18 Impact factor: 20.096
Authors: John M Hollingsworth; David C Miller; Stephanie Daignault; Brent K Hollenbeck Journal: J Natl Cancer Inst Date: 2006-09-20 Impact factor: 13.506
Authors: Christopher J Long; Daniel J Canter; Alexander Kutikov; Tianyu Li; Jay Simhan; Marc Smaldone; Ervin Teper; Rosalia Viterbo; Stephen A Boorjian; David Y T Chen; Richard E Greenberg; Robert G Uzzo Journal: BJU Int Date: 2012-01-05 Impact factor: 5.588
Authors: Mark W Ball; Michael A Gorin; Sam B Bhayani; Craig G Rogers; Michael D Stifelman; Jihad H Kaouk; Homayoun Zargar; Susan Marshall; Jeffrey A Larson; Haider M Rahbar; Bruce J Trock; Phillip M Pierorazio; Mohamad E Allaf Journal: Urol Oncol Date: 2014-12-11 Impact factor: 3.498
Authors: Okyaz Eminaga; Eugene Shkolyar; Bernhard Breil; Axel Semjonow; Martin Boegemann; Lei Xing; Ilker Tinay; Joseph C Liao Journal: Cancers (Basel) Date: 2022-06-26 Impact factor: 6.575